Introduction
============

Cancer cell clones evolve over the lifespan a tumour \[[@B1]-[@B3]\]. The selective pressures driving this clonal evolution are myriad and may include microenvironmental factors, immune system surveillance, competition with other cancer and somatic cells, and selective killing of cancer cells by surgery, chemotherapy and radiation \[[@B2]-[@B9]\]. Two features of cancer portend intense natural selection among cancer cells. The first is the observation that cancer cells (at least in the later stages of growth) experience a high rate of cell death \[[@B10]\]. The second is the greatly increased rate of mutations in cancer cells \[[@B11]-[@B16]\]. For example, a recent large scale study identified mutations in 11% of protein coding genes examined over 756 cancer cell lines \[[@B17]\]. Many of these mutations, even if they change the resulting protein sequence of the gene product may be considered to be "passenger" mutations that do not contribute to oncogenesis \[[@B16]\] and are of no significance to the cancer cell \[[@B3],[@B12]\]. Indeed mutations in non-essential genes may even be adaptive to the cancer cell as they shed costly metabolic processes irrelevant to reproduction of the cancer cell \[[@B3]\].

The high mutation rate and rapid cellular turnover may be expected to form an intense environment for natural selection where mutations arise and are tested for functional importance through competition with other cells. Eventually, this environment may lead to the situation where many genes have been rendered nonfunctional by mutations and the subset of genes that have been important for the survival and multiplication of the cancer cells will have been preserved through constant selection of functional versions of these genes.

Evolutionary biologists have identified a number of methods for detecting molecular evidence of natural selection \[[@B18]\]. These, so-called "tests of selection" attempt to differentiate neutral evolution (i.e. genetic drift) from Darwinian selection. One commonly used method compares ratios of synonymous and non-synonymous base substitutions. This approach has the advantage of being robust with regards to population growth \[[@B18]\], a confounding factor particularly important in the context of cancer cell growth. Synonymous base substitutions change the exonic base pair sequence but conserve the translated amino acid sequence (because of the degenerate nature of the DNA code). In contrast, nonsynonymous base pair substitutions change both the base pair sequence as well as the translated amino acid sequence. An increased rate of synonymous to nonsynonymous base substitutions provides evidence that the base sequence in question is or has been under natural selection to conserve the amino acid sequence (purifying selection). Less commonly, a sequence may exhibit an increased rate of nonsynonymous to synonymous base substitutions, indicating the base sequence in question has been under natural selection to change the ancestral amino acid sequence (diversifying selection). Perhaps the best described example of this is the diversifying selection shaping the peptide binding grooves of MHC class I molecules \[[@B19]\]. We might expect that the majority of selection pressures on cancer cells would be in the form of purifying selection to maintain the function of essential genes. However it is also possible that diversifying selection also plays a role in cancer cell evolution, possibly in facilitating the exploitation of new microenvironments.

Here we test the hypothesis that due to the high mutation rates and increased cell turnover in cancer cells, genes of importance to the survival of the cancer cell should show molecular evidence of natural selection. Furthermore, we predict that in the majority of cases this selection would be in the form of purifying selection.

Materials and methods
=====================

As an initial test of this hypothesis we obtained cancer-derived DNA sequences from GenBank using the search parameters "carcinoma expression library\", \"cancer-associated transcript", \"tumour-associated transcript\" and "*Homo sapiens"*. We did not attempt to obtain an exhaustive list of all available transcripts but rather sought a convenience sample of different genes where at least two different examples of the same gene sequence from cancer tissue could be obtained. We did not include animal model-derived sequences or experimental cell line sequences. To determine if these genes show natural selection in non-cancerous tissues, Genbank was again used to find non-cancer versions of the same genes. In cases where we could not locate two non-cancer sequences from among the GenBank entries, we isolated the relevant sequences from the NCBI reference sequences primary and alternate assemblies. The sequences used in this study are all publically available from NCBI; the sequence references are given in Table [1](#T1){ref-type="table"}.

###### 

Gene sequences used in the analyses

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Gene**   **GenBank Accession Numbers (cancer-related sequences)**         **Probability of Null hypothesis (Hs=Hn) in cancer-related sequences**   **Type of selection**   **P-distance**   **GenBank Accession Numbers (non- cancer-related sequences)**      **Probability of Null hypothesis (Hs=Hn) in non-cancer-related sequences**   **Type of selection**   **Gene function**
  ---------- ---------------------------------------------------------------- ------------------------------------------------------------------------ ----------------------- ---------------- ------------------------------------------------------------------ ---------------------------------------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------------
  EGFR       GI:998566 GI:998564                                              0.603                                                                    none                    0.290            GI:229892268 GI:229892301 GI:229892299                             0.212                                                                        none                    Growth factor receptor

  LNCaP      GI:429094 GI:429093 GI:429091                                    0.771                                                                    none                    0.550            GI:19924155 GI:19924154                                            1.000                                                                        none                    protease present in seminal plasma

  HYAL1      GI:24497567 GI:24497563 GI:24497560                              0.088                                                                    none                    0.054            GI:386365498 GI:385648248 GI:385648249                             0.751                                                                        none                    candidate tumor suppressor\
                                                                                                                                                                                                                                                                                                                                                                        locus

  ALDOA      GI:15488980 GI:15277570 GI:38197497                              0.234                                                                    none                    0.090            GI:342187210 GI:342187198 GI:342187192                             0.331                                                                        none                    glycolytic enzyme

  PTPN3      GI:223941890 GI:223941884 GI:223941878                           0.214                                                                    none                    0.037            GI:223941893 GI:223941875                                          0.081                                                                        none                    protein tyrosine phosphatase

  NBL1       GI:323462168 GI:323276671 GI:323462166 GI:323462167              0.794                                                                    none                    0.045            NC_000001.10 AC_000133.1                                           0.549                                                                        none                    bone morphogenetic protein antagonist

  BLCAP      GI:47939094 GI:28839694                                          0.385                                                                    none                    0.033            GI:268370219 GI:268370215 GI:268370223 GI:268370217                0.077                                                                        none                    tumour suppression gene

  PRKA       GI:331284157 GI:116174749 GI:331284159                           0.077                                                                    none                    0.000            GI:331284154 GI:331284152 GI:331284159                             0.497                                                                        none                    regulates the effect of the cAMP-dependent protein kinase signaling pathway

  STEAP2     GI:350276262 GI:350276256 GI:350276260                           0.301                                                                    none                    0.128            GI:100913195 GI:100913193 GI:100913197                             0.484                                                                        none                    metalloreductase

  MAGED2     GI:41350319 GI:29171703 GI:29171704                              0.899                                                                    none                    0.015            NC_000023.10 AC_000155.1                                           0.034                                                                        diversifying            negative regulator of wild type p53 activity

  FOLR1      GI:262331568 GI:262331573 GI:262331571 GI:262331569              0.470                                                                    none                    0.007            NC_000011.9 AC_000143.1                                            1.000                                                                        none                    folate receptor

  EWSR1      GI:48734726 GI:38197249 GI:15029674 GI:13435962                  0.310                                                                    none                    0.072            GI:253970505 GI:253970501 GI:253970497 GI:253970503                0.171                                                                        none                    involved gene expression, cell signaling, and RNA processing and transport

  SHARPIN    GI:21706472 GI:19264111                                          0.451                                                                    none                    0.003            GI:333805638 GI:118918414                                          0.290                                                                        none                    Involved in NF-kappa-B activation and regulation of inflammation

  NUDCD1     GI:13111833 GI:27694435 GI:21411491                              0.806                                                                    none                    0.005            GI:189571676 GI:189571678                                          0.071                                                                        none                    tumor-associated antigen

  PMEPA1     GI:51593770 GI:16198474 GI:22121998 GI:9255808                   0.878                                                                    none                    0.032            GI:40317615 GI:40317617 GI:40317619                                0.353                                                                        none                    Involved in down-regulation of the androgen receptor

  CTAGE5     GI:313882513 GI:30411006 GI:39963693 GI:24659234                 0.244                                                                    none                    0.007            GI:134053863 GI:134053924 GI:134053890                             0.002                                                                        purifying               tumor-associated antigen

  IRAK3      GI:34785939 GI:46854383                                          0.791                                                                    none                    0.003            GI:216547518 GI:216547503                                          1.000                                                                        none                    receptor-associated kinase

  PLS3       GI:34785158 GI:25058020 GI:288915540                             0.255                                                                    none                    0.015            GI:288915537 GI:288915538                                          0.243                                                                        none                    actin-bundling protein

  PRAME      GI:33874094 GI:25123208 GI:21328745                              0.121                                                                    none                    0.019            GI:46249372 GI:46249366 GI:46249370 GI:46249365                    0.754                                                                        none                    transcriptional repressor

  TNFSF13    GI:33873809 GI:24934971 GI:211938417                             0.211                                                                    none                    0.162            GI:211938416 GI:310750386 GI:310750384                             1.000                                                                        none                    possibly involved in regulation of tumor cell growth and monocyte/macrophage-mediated immunological processes

  ENOX2      GI:17939422 GI:80478559                                          0.070                                                                    none                    0.006            GI:32528292 GI:32528290                                            1.000                                                                        none                    growth-related cell surface protein

  UQCC       GI:114108213 GI:77415336 GI:111598967 GI:296923772               0.452                                                                    none                    0.008            GI:296923778 GI:296923775                                          1.000                                                                        none                    enzyme involved in ubiquinol-cytochrome c reductase complex

  ALOX15B    GI:85067502 GI:85067498 GI:39645887 GI:85067500                  0.085                                                                    none                    0.001            GI:182765463 GI:260166611                                          1.000                                                                        none                    involved in the production of fatty acid hydroperoxides

  TACSTD2    GI:166795235 GI:238914823 GI:14495610                            0.340                                                                    none                    0.014            NM_002353\                                                         1.000                                                                        none                    cell surface receptor that transduces calcium signals
                                                                                                                                                                                                AC_000133                                                                                                                                                               

  RAET1E     GI:149790140 GI:73909189                                         0.197                                                                    none                    0.151            GI:21040248 GI:341915375 GI:343183384                              0.586                                                                        none                    delivers activating signals to NK cells

  MAGEB1     GI:15489350 GI:164693182 GI:49456482                             0.337                                                                    none                    0.011            GI:284004909 GI:257796251 GI:257796250                             0.0151                                                                       purifying               tumor-associated antigen

  CSF1       GI:18088910 GI:166235151                                         0.413                                                                    none                    0.142            GI:347360911 GI:166235149 GI:384475524                             0.657                                                                        none                    cytokine that controls the production, differentiation, and function of macrophages

  CKAP2      GI:148664243 GI:148664200 GI:187950332 GI:15012012               0.278                                                                    none                    0.084            NC_000013.10\                                                      0.320                                                                        none                    involved in regulating aneuploidy, cell cycling, and cell death
                                                                                                                                                                                                AC_000145.1                                                                                                                                                             

  MUC1       GI:182252 GI:115528448 GI:324120948                              0.085                                                                    none                    0.389            GI:324120957 GI:324120955 GI:324120951 GI:324120950                0.716                                                                        none                    adhesion and anti-adhesion protein; involved in cell signaling

  TMPRSS3    GI:14709533 GI:33991397 GI:145701031                             0.736                                                                    none                    0.008            GI:291167774 GI:145701029 GI:291167776                             1.000                                                                        none                    serine protease; plays a role in hearing

  FOLR2      GI:34785969 GI:166064049 GI:166064051                            0.090                                                                    none                    0.005            GI:166064049 GI:166064053 GI:166064055                             1.000                                                                        none                    folate receptor

  BYF3       GI:33873803 GI:110624585 GI:83641884 GI:83641883                 0.137                                                                    none                    0.049            GI:224177471 GI:1435190 GI:179571 GI:179575                        0.686                                                                        none                    involved in transcriptional initiation

  TPBG       GI:33872201 GI:262205658 GI:262205664                            0.807                                                                    none                    0.012            NC_000006.11 AC_000138.1                                           0.521                                                                        none                    possible cell adhesion molecule

  EMP2       GI:16307197 GI:64692933                                          0.298                                                                    none                    0.002            NC_000016.9 AC_000148.1                                            1.000                                                                        none                    epithelial membrane protein

  TGM6       GI:33331029 GI:33331031                                          1.00                                                                     none                    0.000            NC_000020.10 AC_000152.1                                           0.266                                                                        none                    associated with central nervous system development and motor function

  NBR1       GI:112382227\                                                    0.359                                                                    none                    0.504            GI:33869357 GI:111120332                                           0.018                                                                        purifying               Function unknown
             GI:112382229\                                                                                                                                                                                                                                                                                                                                              
             GI:112382228                                                                                                                                                                                                                                                                                                                                               

  CALM2      GI:19913528 GI:16924228 GI:14250064                              0.04                                                                     diversifying            0.524            GI:229577210 GI:13097164                                           0.026                                                                        diversifying            Mediates enzymes, ion channels and other proteins

  NRG1       GI:49522882 GI:34782767 GI:33873543                              0.012                                                                    purifying               0.220            GI:236460384 GI:236464355                                          1                                                                            none                    signaling protein that mediates cell-cell interactions

  SYTL2      GI:244790015 GI:244790004 GI:244790009 GI:244790019              0.012                                                                    purifying               0.097            GI:82571721 GI:34784984 GI:21951814 GI:21984183                    0.482                                                                        none                    Involved in vesicle trafficking and melanosome distribution

  BCAP31     GI:213511729 GI:213511011 GI:213511507 GI:40807164 GI:15680022   0.048                                                                    purifying               0.055            GI:374253795 GI:374253793                                          0.083                                                                        none                    multi-pass endoplasmic reticulum transmembrane protein

  ILK        GI:3150001 GI:16306740 GI: 8648884                               0.013                                                                    purifying               0.007            GI:62420874 GI:62420871 GI:62420872 GI:8308037                     0.222                                                                        none                    serine/threonine protein kinase

  LIMS1      GI:13529136 GI:336455030                                         0.016                                                                    purifying               0.007            GI:164697166 GI:34528462 GI:336455029                              \<0.001                                                                      purifying               likely involved in integrin signaling

  CHST4      GI:23273964 GI:262205557 GI:262205902                            0.016                                                                    purifying               0.021            GI:262205902 GI:262205557                                          0.018                                                                        purifying               sulfotransferase; modifies glycan structures on ligands of the lymphocyte homing receptor L-selectin

  EBAG9      GI:17389375 GI:13528905 GI:18490914                              0.009                                                                    purifying               0.072            GI37694064 GI:37694063 GI:158254733                                0.289                                                                        none                    tumor-associated antigen

  NACA       GI:76779232 GI:333033786 GI:163965363                            0.002                                                                    purifying               0.186            GI:85397251 GI:85397957 GI:60116922                                0.755                                                                        none                    Component of nascent polypeptide-associated complex; prevents mistranslocation of proteins

  OCIAD1     GI:13097314 GI:56789926                                          0.036                                                                    purifying               0.065            GI:269914125 GI:269914123 GI:269914126 GI:269914124 GI:269954665   0.005                                                                        purifying               tumor-associated antigen
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

P-distances are given for cancer-associated sequences only. See text for further explanation.

Analyses were performed using the Molecular Evolutionary Genetics Analysis (MEGA) software Version 5 \[[@B20]\]. Following sequence alignment using the ClustalW method, the Nei-Gojobori Z-Test of Selection \[[@B21]\] was used to calculate the synonymous to nonsynonymous base substitution rates and the associated statistical probabilities. P-values of less than 0.05 were considered significant.

Results
=======

A total of 46 cancer-derived genes represented by 139 sequences were identified (Table [1](#T1){ref-type="table"}). No sequences were derived from propagated cell lines. However, we were unable to determine what proportion of examples were from primary tumors vs metastatic tumors. Of the 46 genes, nine genes showed evidence of purifying selection and 1 showed evidence of diversifying selection (Table [1](#T1){ref-type="table"}). Six genes showed molecular evidence of selection only in cancer associated sequences (all in the form of purifying selection), four genes showed evidence of selection only in non-cancer associated sequences (three cases of purifying selection and one case of diversifying selection), and finally four genes showed molecular evidence of selection in both cancer and non-cancer associated sequences (three cases of purifying selection and one case of diversifying selection; Table [1](#T1){ref-type="table"}). Table [1](#T1){ref-type="table"} also gives the GenBank accession numbers for all sequences used as well as sequence divergence estimates (p-distances) and the results of the Nei-Gojobori Z-tests of selection.

If signatures of selection become more common as mutations accumulate in a cancer-associated sequence, we might expect to see greater nucleotide divergence estimates in examples showing significant selection. To test this, we compared p-distances in the 10 examples showing molecular evidence of selection in the cancer associated sequences with the 36 examples not showing evidence of selection in the cancer associated sequences. The mean p-distance of sequences showing evidence of selection was 0.125, while the mean p-distance of sequences not showing evidence of selection was 0.082 (unpaired *t*-test, p=0.398).

Discussion
==========

We describe a proof of principle test of a method of identifying molecular signatures of natural selection in cancer-derived gene sequences. We also show that in a sample of 46 genes the cancer and non-cancer derived sequences show different patterns of selection.

As a cancer grows and evolves and different genes come under selection pressure, natural selection may be expected to record evidence of this selection in the proportion of synonymous to nonsynonymous base substitutions as we have discussed here. Even if that particular gene later becomes non-functional through further mutations, evidence of prior selection pressure would be expected to persist. Thus a list of genes showing molecular evidence of selection only in cancer cells could be considered to be those genes which have been important to the survival of the cancer cell up to that point on time. In essence, this provides us with a method to determine which genes have been integral to the survival the cancer cell.

There are several potential weaknesses to our study. First, a different number of sequences were available for the various genes we examined. With a greater number of sequences we may expect a greater power to detect signatures of selection. To test such an effect we compared the mean number of sequences from genes which showed selection (3.17) to the mean number of sequences from genes which did not show selection (3.27). The difference was not statistically significant (p=0.134, unpaired *t*-test). Therefore, although this is a potential theoretical concern, we can find no evidence of this in our data.

Second, we do not have information about the geographic or racial origins of the individuals from whom the cancer and non-cancer gene sequences were derived. It is possible that increased variability noted for some genes could be due to these factors.

Third and perhaps most importantly, the choice of the model to calculate dN/dS as well as the test interpretation are both potentially controversial. The Nei-Gojobori method is perhaps less conservative than a maximum likelihood model but at the same time if the majority of sites in a protein evolve under purifying selection (as we might expect in a functionally essential gene in a tumour) the dN/dS statistic has reduced sensitivity to detect positive selection \[[@B22]\]. Moreover, the behaviour of dN/dS statistics when applied to polymorphisms within a population may behave differently than when applied to fixed mutations between species \[[@B23]\]. Whether cancer cells from the same tumour and/or from tumours from different individuals are sufficiently diverged to be considered analogous to different species \[[@B24]\] is a critical unanswered question. Therefore, because of these uncertainties, we decided to use the simple Nei-Gojobori statistic for this preliminary analysis. As major cancer sequencing initiatives begin producing whole genome sequences from paired cancer/normal samples from the same patient, this question will become more important. Further work should critically examine the optimal statistic to be used for these analyses.

Although we could not detect a statistically significant difference in the mean p-distances between cancer associated sequences showing evidence of selection and those that did not, there was a trend toward greater p-distances among the sequences showing selection and so our inability to demonstrate a difference may be a factor of the limited sample size.

Parenthetically, the process postulated here, where relentless mutation in cancer cells results in either mutational inactivation of genes or positive selection to maintain their function gives a functional explanation for why more advanced cancers invariably show what pathologists refer to as "de-differentiation"; as Mueller's ratchet \[[@B25]\] removes all but the reproductively essential genes.

It will be obvious that the ability of gene sequences to display evidence of natural selection is based both on a high cancer cell mutation rate and an increased cancer cell proliferative rate which together provide the raw material on which selection can act. As these conditions likely are greater in more advanced cancers, we would expect to see greater molecular evidence of selection in later stage cancer cells. Indeed, comparison of early and later stage cancer cells could provide a roadmap of when particular genes experience selection pressure and therefore when these genes are important for tumorigenesis. Furthermore, because the molecular signatures of selection would be expected to persist for many generations of cancer cells, late stage cancers would be expected to contain a molecular record of genes conserved at essentially any stage of the clonal evolution of the cancer cell, even if that gene is no longer under selection pressure or even is no longer functional. By this line of reasoning, genes which are epigenetically silenced would be shielded from selection and may be expected to eventually be subject to loss of function mutations, even if they maintain molecular evidence of prior natural selection during tumorigenesis.

We caution that our results with regards to specific genes should be interpreted as preliminary only. Our sample was based only on publicly available sequences and encompassed a number of different malignancies making any conclusions about gene function based on these findings premature. Furthermore, this approach may not distinguish between driver genes which promote oncogenesis and non-driver genes nevertheless essential for cancer cell growth and reproduction. However, the application of previously described methods could be used to distinguish these \[[@B16],[@B17]\].

As new databases of cancer genomes become available \[[@B14],[@B17]-[@B27]\], a future direction for this work will be to apply these techniques to whole genome sequences of cancer cells. This could be performed at the level of the tumour as a whole to look at genes important across a sample of tumours of the same type or it could be applied to single cells to explore the genes of importance in particular microenvironments such as metastatic deposits. This approach, combined with oncogenetic reconstruction of cancer clonal lineages using the same sequencing data could provide a powerful new tool to identify candidate genes of functional significance for potential targeted therapies as well as providing new insights into the evolutionary mechanisms of cancer cell clonal evolution.

Conclusions
===========

Genes may be under different selection pressures within a cancer as compared to normal tissues. In this paper we proposed a method to answer the question of what genes are important to a cancer cell. The high mutation rates and rapid cell division present in cancer suggests that functionally important genes will show evidence of selection. We could therefore, in an indirect manner, observe what genes a cancer cell needs to survive. The genes that are important could then form a list of possible targets for therapeutic intervention.
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